BX Swiss TOP 30 CHF

BX Swiss TOP 30 CHF handeln
1.428,93 PKT +17,88 PKT +1,27 %
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

WKN SL0CLV

ISIN DE000SL0CLV3


Analysen zu BX Swiss TOP 30 CHF-Werten

Datum Rating Analyst
13.06.12 Holcim neutral J.P. Morgan Cazenove
13.06.12 Zurich Insurance buy Vontobel Research
13.06.12 Holcim buy Société Générale Group S.A. (SG)
13.06.12 Swiss Re buy Vontobel Research
12.06.12 UBS neutral UBS AG
12.06.12 Julius Bär buy UBS AG
12.06.12 UBS sell Société Générale Group S.A. (SG)
12.06.12 Swiss Life buy Nomura
12.06.12 UBS hold Société Générale Group S.A. (SG)
11.06.12 Nestlé hold Société Générale Group S.A. (SG)
11.06.12 UBS hold Commerzbank Corp. & Markets
11.06.12 Roche neutral J.P. Morgan Cazenove
11.06.12 Roche neutral Nomura
11.06.12 Novartis hold Vontobel Research
08.06.12 Novartis neutral J.P. Morgan Cazenove
08.06.12 ABB (Asea Brown Boveri) buy Citigroup Corp.
08.06.12 UBS buy WestLB AG
08.06.12 Logitech neutral Sarasin Research
08.06.12 Logitech hold Vontobel Research
07.06.12 Roche buy Société Générale Group S.A. (SG)
06.06.12 Holcim neutral Goldman Sachs Group Inc.
06.06.12 Holcim sell Goldman Sachs Group Inc.
06.06.12 Geberit hold Vontobel Research
05.06.12 Straumann underperform Exane-BNP Paribas SA
05.06.12 Roche outperform Exane-BNP Paribas SA
05.06.12 Novartis hold Vontobel Research
04.06.12 Novartis neutral Exane-BNP Paribas SA
04.06.12 Roche neutral Citigroup Corp.
04.06.12 Swiss Re neutral Exane-BNP Paribas SA
04.06.12 Novartis neutral Citigroup Corp.
04.06.12 Straumann hold Vontobel Research
04.06.12 Novartis hold Vontobel Research
04.06.12 Zurich Insurance buy Vontobel Research
01.06.12 Swiss Re buy UBS AG
01.06.12 Swiss Re hold Société Générale Group S.A. (SG)
01.06.12 Kühne + Nagel International underperform Cheuvreux SA
01.06.12 Lonza hold Vontobel Research
31.05.12 Swiss Re overweight J.P. Morgan Cazenove
31.05.12 ABB (Asea Brown Boveri) neutral Exane-BNP Paribas SA
31.05.12 Swiss Re buy Sarasin Research